Background Feline inflammatory aural polyps (IP) have been reported as solitary growths, yet bilateral polyps may occur more commonly than described previously. Objectives To identify the prevalence and risk factors associated with bilateral feline IP within a population of cats evaluated at a veterinary teaching hospital over a 10 year period. Animals Twenty‐five cats with histologically confirmed IP. Methods and materials A retrospective study was performed by searching computerized medical records of cats seen at The University of Tennessee Veterinary Teaching Hospital from 2005 to 2015. Keywords used for the search included “feline polyp”, “ventral bulla osteotomy”, “inflammatory polyp ear canal” and “nasopharyngeal polyp”. Results Cats were separated into groups with unilateral or bilateral disease. Six of 25 (24%) cats had bilateral IP. Twelve cats had computed tomography performed (four of six with bilateral IP; eight of 19 with unilateral IP). Clinical signs, history of upper respiratory infection, post‐treatment complications, and IP recurrence with and without local and systemic steroid administration were studied between groups and no differences were identified. In four of six cats with bilateral disease, the second polyp was identified with advanced imaging performed at the time of referral. Conclusions and clinical importance These findings demonstrate that bilateral IP occur more frequently than reported previously and establish a prevalence for bilateral IP. These findings also highlight the value of advanced imaging techniques in diagnosing bilateral IP.
Background Testing for hyperadrenocorticism is commonly pursued in adult dogs with dermatological disease, and adrenocortical suppression has been well‐documented following the use of topical corticosteroids in otic preparations. An otic suspension that contains florfenicol, terbinafine and mometasone furoate, and lasts for 30 days after a single application, frequently is used to treat canine otitis externa (OE). This medication was shown to cause adrenocortical suppression on Day (D)2 postadministration and two weeks after two applications two weeks apart. Hypothesis/objectives The objective of this study was to determine if topical florfenicol/terbinafine/mometasone furoate causes adrenocortical suppression in healthy, small‐breed dogs with bilateral OE at D28 postapplication. Animal Seven client‐owned dogs weighing <10 kg diagnosed with non‐Pseudomonas bilateral OE. Materials and methods Cortisol was measured pre‐ and post‐adrenocorticotropic (ACTH) stimulation on D0. Topical florfenicol/terbinafine/mometasone furoate was applied in both ears. Dogs were reassessed on D28, and cortisol was measured pre‐ and post‐ACTH stimulation. Results The median pre‐ and post‐ACTH cortisol concentrations on D28 were 2.5 µg/dL (range 2.0–5.0 µg/dL) and 14.3 µg/dL (range 11.5–23.1 µg/dL), respectively. There was no significant difference (P = 0.85) between post‐ACTH cortisol concentrations from D0 to D28. Conclusions and clinical relevance Results demonstrated no evidence of adrenocortical suppression, suggesting that there is no need to delay adrenocortical function testing in dogs treated with topical florfenicol/terbinafine/mometasone furoate when applied as per the manufacturer’s recommendations.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.